# Lenalidomide Based Immunotherapy in the Treatment of DLBCL

> **NCT03715296** · — · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Lenalidomide 25mg

## Key facts

- **NCT ID:** NCT03715296
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-18
- **Primary completion:** 2020-09-15
- **Final completion:** 2020-09-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2019-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03715296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03715296, "Lenalidomide Based Immunotherapy in the Treatment of DLBCL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03715296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*